Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates
Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 47.37% and 64.42%, respectively, for the quarter ended March 2025. Do…
172,360$
0,02%
Echtzeit-Aktienkurs Reata Pharmaceuticals
Bid:
Ask:
Nachrichten zur Reata Pharmaceuticals Aktie
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical…
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical…
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical…
Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript
…
Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript
…
Atea Pharmaceuticals, Inc. (AVIR) Q1 2024 Earnings Call Transcript
…
Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Transcript
…
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged…
Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript
…